Euronext N.V.. (2/8/17). "Press Release: Lysogene Lists on Euronext. €22.6 Million Raised, Market Capitalisation of approximately €82 Million". Paris.

	Region	Paris
	Country	France
	Organisation	Lysogene S.A. (Euronext Paris: LYS)
	Organisation 2	Euronext Paris S.A.
	Group	Euronext (Group)
	Product	gene therapy
	Product 2	financial services
	Index term	Lysogene–SEVERAL: investment, 201701–201702 IPO €22.6m w 3.32m new shares at €6.8/share at Euronext Paris
	Person	Aiach, Karen (Lysogene 201206 CEO + Founder)

Euronext today welcomed Lysogene, a company specialized in gene therapy targeting two rare diseases of the central nervous system, to Compartment C of its regulated market in Paris. Lysogene is the first biotechnology company to join the Paris market in 2017.

A pioneer in gene therapies, Lysogene is developing new drug candidates to treat two rare, devastating and fatal central nervous system disorders in children for which, to the best of the Company’s knowledge, no current treatment exists: Sanfilippo syndrome type A (MPS IIIA) and GM1 gangliosidosis (or Landing disease). The group’s aim is to develop and make available to young patients safe, innovative treatments that can correct the dysfunction of their defective gene, thus leading to radical improvements in quality of life for them and their family. Its aim is also to reduce the societal and financial impact of dealing with such diseases in the absence of a dedicated, safe and efficient therapy.

Lysogene (ticker symbol: LYS) was listed through the admission to trading on February 8, 2017 of a total 12,078,704 shares, including 3,323,567 new shares issued through a Global Offering[1].

The offering price was set at €6.80 euros per share. Lysogene’s market capitalisation was approximately € 82.1 million on the day of listing, and the transaction raised a total of €22.6 million.

Lysogene joins the 45 biotechnology companies already listed on Euronext markets, which together represent a total capitalisation of €12 billion. In just a few years Euronext has become the European benchmark for life science businesses, and reinforces the segment’s visibility with its recently launched Baromètre Biotech.

At the listing ceremony, Karen Aiach, founder and CEO of Lysogene, said “Listing is a major step for Lysogene, and one that will help us continue to develop treatments for two devastating diseases creating multiple disabilities that begin in childhood and lead to the premature death of patients. We would like to extend our sincere thanks to the shareholders that have supported us along the way, including Sofinnova Partners, BpiFrance Investissement (InnoBio) and Novo A/S, as well as the new partners that have joined us today, including Financière Arbevel and Alto Invest.”

[1] The Global Offering was made up of a Public Offering that included an Open Price Public Offering in France and a Global Placement with institutional investors in France and other countries

About Lysogene

Lysogene is a clinical-stage biotechnology company pioneering the basic research and clinical development of gene therapies that use vectors derived from adeno-associated viruses to treat rare and fatal central nervous system disorders in children, for which, to the best of the Company’s knowledge, no current treatment exists. Since 2009, Lysogene has established a solid platform and extensive network, along with innovative products in MPS IIIA and GM1 Gangliosidosis, to become a global leader in gene therapies for rare and fatal central nervous system diseases.
For more information: www.lysogene.com

About Euronext

Euronext is the leading pan-European exchange in the Eurozone with more than 1 300 listed issuers worth close to €3.3 trillion in market capitalization as of end December 2016, an unmatched blue chip franchise consisting of 25 issuers in the EURO STOXX 50® benchmark and a strong diverse domestic and international client base.

Euronext operates regulated and transparent equity and derivatives markets. Its total product offering includes Equities, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. Euronext operates regulated markets, Alternext and the Free Market; in addition it offers EnterNext, which facilitates SMEs’ access to capital markets.

For the latest news, find us on Twitter (twitter.com/euronext) and LinkedIn (linkedin.com/euronext).

Disclaimer

This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided “as is” without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.

This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at www.euronext.com/terms-use.

Record changed: 2023-06-05